We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

9 hedge funds and large institutions have $9.03M invested in Altamira Therapeutics Ltd in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 9 → 9 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

23% less capital invested

Capital invested by funds: $11.7M → $9.03M (-$2.68M)

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$169K
2
VKH
Virtu KCG Holdings
New York
+$113K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$368K
2
UOC
UBS O'Connor
Illinois
-$113K
Name Holding Trade Value Shares
Change 		Change in
Stake
SMV
1
Sofinnova Management VIII
California
$5.63M – – –
BG
2
Bellevue Group
Switzerland
$1.55M – – –
UOC
3
UBS O'Connor
Illinois
$575K -$113K -2 -17%
TCM
4
Tekla Capital Management
Massachusetts
$554K – – –
Morgan Stanley
5
Morgan Stanley
New York
$265K +$169K +3 +150%
SM
6
Sabby Management
Florida
$103K – – –
VKH
7
Virtu KCG Holdings
New York
$101K +$113K +2 New
WA
8
Wasatch Advisors
Utah
$83K – – –
WS
9
Wedbush Securities
California
$32K – – –
SPC
10
Sigma Planning Corp
Michigan
$26K – – –
TSS
11
Two Sigma Securities
New York
$23K – – –
UBS Group
12
UBS Group
Switzerland
$22K – – –
KeyBank National Association
13
KeyBank National Association
Ohio
$17K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$14K – – –
ARTA
15
A.R.T. Advisors
New York
$11K – – –
Bank of New York Mellon
16
Bank of New York Mellon
New York
$8K – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$8K – – –
BTS
18
BB&T Securities
Virginia
$7K – – –
CG
19
Cutler Group
California
$4K – – –
Creative Planning
20
Creative Planning
Kansas
$1K – – –
PA
21
Perceptive Advisors
New York
– -$368K -5 Closed

CYTO Hedge Fund Activity: Q2 2017 in Review

9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2017, worth a combined $9.03M — down 23% from $11.7M a quarter earlier.

Fund positioning in CYTO was balanced in Q2 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $169K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $368K sold.

  • 9 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $9.03M of Altamira Therapeutics Ltd stock for Q2 2017, down 23% quarter-over-quarter.
  • 1 fund opened new Altamira Therapeutics Ltd positions in Q2 2017 and 1 closed out, a net change of 0 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q2 2017 was Morgan Stanley, an estimated $169K added.
  • The largest Altamira Therapeutics Ltd seller in Q2 2017 was Perceptive Advisors, an estimated $368K sold.

Based on aggregated 13F filings for Q2 2017.